Table 1.
Summary of demographic and clinicopathologic characteristics of 858 patients
| Characteristic | Value |
|---|---|
|
| |
| Age at diagnosis (years), Mean (SD) | 51.2 (6.0) |
| Male sex | 428 (49.9%) |
| Site by Sex | |
| Female | |
| Head/neck | 35 (8.1%) |
| Trunk | 144 (33.5%) |
| Upper limb | 130 (30.2%) |
| Lower limb | 121 (28.1%) |
| Male | |
| Head/neck | 89 (20.8%) |
| Trunk | 200 (46.7%) |
| Upper limb | 105 (24.5%) |
| Lower limb | 31 (7.2%) |
| Not documented | 3 (0.7%) |
| Location | |
| Right | 353 (41.1%) |
| Left | 403 (47.0%) |
| Central | 80 (9.3%) |
| Not documented | 22 (2.6%) |
| Preexisting nevus | |
| Absent | 253 (29.5%) |
| Compound nevus | 27 (3.1%) |
| Dermal nevus | 34 (4.0%) |
| Nevus not otherwise specified | 84 (9.8%) |
| Not documented | 460 (53.6%) |
| Clark level | |
| I | 196 (22.8%) |
| II | 339 (39.5%) |
| III | 180 (21.0%) |
| IV | 120 (14.0%) |
| V | 10 (1.2%) |
| Not documented | 13 (1.5%) |
| Base transected | 804 (93.7%) |
| Positivity of margin at initial incision | |
| Yes | 298 (34.7%) |
| < 1mm | 156 (18.2%) |
| No | 348 (40.6%) |
| Not documented | 56 (6.5%) |
| Invasive or in situ | |
| Invasive | 659 (76.8%) |
| In situ | 195 (22.7%) |
| Not documented | 4 (0.5%) |
| Histogenic type of in situ melanoma | |
| (N=195) | |
| Lentigo Maligna in situ | 56 (28.7%) |
| Superficial spreading in situ | 71 (36.4%) |
| Malignant melanoma in situ | 60 (30.8%) |
| Acral lentiginous | 1 (0.5%) |
| Not documented | 7 (3.6%) |
| Among invasive melanoma only (N=659) | |
| Histogenic type | |
| Lentigo Maligna | 43 (6.5%) |
| Superficial spreading | 492 (74.7%) |
| Nodular | 38 (5.8%) |
| Desmoplastic | 3 (0.5%) |
| Acral lentiginous | 9 (1.4%) |
| Mixed | 2 (0.3%) |
| Other | 7 (1.1%) |
| Not documented | 65 (9.9%) |
| Breslow depth or thickness (mm) | |
| Median (interquartile range) | 0.5 (0.3, 0.8) |
| <1.00 | 532 (80.7%) |
| 1.01–2.00 | 68 (10.3%) |
| 2.01–4.00 | 31 (4.7%) |
| >4.00 | 14 (2.1%) |
| Not documented | 14 (2.1%) |
| Pathologic stage (AJCC 8th edition) | |
| IA | 502 (76.2%) |
| IB | 84 (12.7%) |
| IIA | 17 (2.6%) |
| IIB | 15 (2.3%) |
| IIC | 3 (0.5%) |
| III | 22 (3.3%) |
| IV | 9 (1.4%) |
| Not documented | 7 (1.1%) |
AJCC: American Joint Committee on Cancer